Switch View
© BusinessWire
13.11.2025
ISIN: US1710774076
Niagen Bioscience Inc
CDXC
LISTED
NASDAQ
Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)
News Preview
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of Tru Niagen® Beauty, the first-ever beauty supplement in the US featuring Niagen (patented nicotinamide riboside or NR) — the most efficient, effective, and high quality...
Themefolio
Profiler
Peergroup
© ActuNews
13.11.2025
ISIN: FR0000061129
Boiron SA
BOI
LISTED
EURONEXT
BOIRON : Déclaration des droits de vote au 31 octobre 2025
News Preview
Le 12 novembre 2025
Publication
du nombre d'actions composant le capital et du nombre total de droits de vote
(articles L. 233-8 II du code de commerce et 223-16 du règlement général de l'AMF)
Date d'arrêt des informations
Nombre total d'actions composant le capital
Nombre total de d...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
ISIN: US24661P8077
Delcath Systems, Inc.
DCTH
LISTED
NASDAQ
Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results from a retrospective analysis conducted by researchers at the University of Tubingen, Germany. The study, titled “Characterization of long...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
13.11.2025
ISIN: US3755581036
Gilead Sciences Inc
GILD
LISTED
NASDAQ
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial
News Preview
Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of adults with HIV who are virologically suppressed switching from a multi-tablet regimen to an investigational single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
13.11.2025
ISIN: US40412C1018
HCA Healthcare Inc
HCA
LISTED
NYSE
HCA Healthcare Surpasses 100,000 Pounds of Collected Medication in Year Seven of Annual “Crush the Crisis”
News Preview
HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced that it collected 19,846 pounds, approximately 13.6 million doses, of unused or expired medications during its seventh annual “Crush the Crisis” national prescription drug take back day. In total, the organization has now collected more than 108,500...
Themefolio
Profiler
Peergroup
© Newsfile
13.11.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
Class Action Lawsuit Filed: Baxter International, Inc. (BAX) - Join by December 15, 2025 - Contact Levi & Korsinsky
News Preview
New York, New York--(Newsfile Corp. - November 13, 2025) - If you suffered a loss on your Baxter International, Inc. (NYSE: BAX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/baxter-international-inc-lawsuit-submission-form?prid=177135...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2025
ISIN: US42226A1079
Healthequity Inc
HQY
LISTED
NASDAQ
HealthEquity to Enhance Member Experience with Agentic AI
News Preview
Nation's Largest HSA Custodian Leverages Parloa’s Advanced AI Technology to Deliver Personalized, Conversational Support for Millions of Members Nation's Largest HSA Custodian Leverages Parloa’s Advanced AI Technology to Deliver Personalized, Conversational Support for Millions of Members...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
ISIN: US7599101026
KORU Medical Systems Inc
KRMD
LISTED
NASDAQ
KORU Medical Systems to Participate in Upcoming Investor Conferences
News Preview
KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will be participating in three upcoming Investor Conferences....
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
ISIN: US68213N1090
Omnicell Inc
OMCL
LISTED
NASDAQ
Omnicell Achieves URAC Certification, Strengthening Compliance and Scalability for Health System-Owned Specialty Pharmacies
News Preview
In a move that reinforces its leadership in enabling health system-owned specialty pharmacy growth, Omnicell, Inc. (Nasdaq:OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy and nursing care delivery model, today announced that its Specialty Pharmacy Services business has earned URAC Health Care Management Certification. Th...
Themefolio
Profiler
Peergroup
© Newsfile
13.11.2025
ISIN: CA14161Y2006
Cardiol Therapeutics Inc
CRDL
LISTED
TSX
Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040
News Preview
Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property protection in the world's largest pharmaceutical market.This allowance fortifies Cardiol's global intellectual property portfolio, adding t...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
ISIN: US2560861096
DocGo Inc
DCGO
LISTED
NASDAQ
DocGo Announces Participation at Upcoming Investor Conferences
News Preview
DocGo Inc. (Nasdaq: DCGO) (“DocGo”), a leading provider of technology-enabled mobile health and medical transportation services, announced today that management will be participating in the following investor conferences in November:
17th Annual Southwest Ideas Conference (November 19th)
Norm Rosenberg, Chief Financial Officer will participate i...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2025
ISIN: US31189P1021
Fate Therapeutics Inc
FATE
LISTED
NASDAQ
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
News Preview
Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate that Utilizes Less-intensive or No Conditioning, Enabling Broad Patient Accessibility...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
13.11.2025
ISIN: US1374041093
Candel Therapeutics, Inc.
CADL
LISTED
NASDAQ
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
News Preview
NEEDHAM, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today financial results for the third quarter ended September 30, 2025, and provided a c...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2025
ISIN: US81063V2043
Odysight.ai Inc
ODYS
LISTED
NASDAQ
Odysight.ai Reports Financial Results for The Nine Months Ended September 30, 2025 and Provides Business Update
News Preview
OMER, Israel, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Odysight.ai Inc. (NASDAQ: ODYS), a leading provider of visual based predictive maintenance (PdM) and condition-based monitoring (CBM) solutions, announces its financial results for the nine months ended September 30, 2025, and provides a business update....
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
ISIN: CA94947L1022
WELL Health Technologies Corp
WELL
LISTED
TSX
WELL Health Provides Corporate Update on WELLSTAR Reflecting Organic and Inorganic Growth Wins
News Preview
WELL Health Technologies Corp. (TSX: WELL, OTCQX: WHTCF) (the “Company” or “WELL”), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to provide a corporate update on its majority-owned platform subsidiary, WELLSTAR Techn...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2025
ISIN: CA58504D1006
Medipharm Labs Corp
LABS
LISTED
TSX
MediPharm Advances Global Reach in Q3 2025 with Double-Digit Revenue Growth and Strong International Medical Cannabis Gains
News Preview
MediPharm delivered another successful quarter of strong year-over-year revenue growth in the three months ended September 30, 2025 ("Q3 2025")....
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2025
ISIN: KYG596651029
MeiraGTx Holdings PLC
MGTX
LISTED
NASDAQ
MeiraGTx Reports Third Quarter 2025 Financial and Operational Results
News Preview
LONDON and NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced financial and operational results for the third quarter ended September 30, 2025, and provided a corporate update....
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2025
ISIN: US6024961012
MiMedx Group Inc
MDXG
LISTED
NASDAQ
MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial
News Preview
Publication of Interim Results and Presentation at Recent Industry Event Demonstrate Clinical Benefit Associated with Use of EPIEFFECT When Compared to Standard of Care (“SOC”)...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2025
ISIN: US23284F1057
CytomX Therapeutics Inc
CTMX
LISTED
NASDAQ
CytomX Therapeutics to Present at the Jefferies London Healthcare Conference
News Preview
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
ISIN: US01438T1060
Aldeyra Therapeutics Inc
ALDX
LISTED
NASDAQ
Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast
News Preview
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced at a research and development webcast the expansion of the RASP platform to include programs in central nervous system diseases associated with inflammat...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2025
ISIN: US92854B1098
Vivani Medical, Inc.
VANI
LISTED
NASDAQ
Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results
News Preview
Company plans to initiate Phase 1 clinical study of semaglutide implant for chronic weight management in the first half of 2026 and parallel investments in studies to enable rapid initiation of Phase 2 dose-ranging study, pending Phase 1 results and regulatory feedback...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Merck to Participate in the Jefferies Global Healthcare Conference in London
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, Human Health U.S., and Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Jefferies Global Healthca...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
ISIN: FR0014000MR3
Eurofins Scientific SE
ERF
LISTED
EURONEXT
Eurofins Scientific SE: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2025
ISIN: US15673T1007
Century Therapeutics Inc
IPSC
LISTED
NASDAQ
Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
PHILADELPHIA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today reported financial results for the third quarter ended September 30, 2025, and provided a business update....
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2025
ISIN: US70465T1079
PDS Biotechnology Corp
PDSB
LISTED
NASDAQ
PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update
News Preview
Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Cancer...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2025
ISIN: CA03879J1003
Arbutus Biopharma Corp
ABUS
LISTED
NASDAQ
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
News Preview
WARMINSTER, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today reported third quarter 2025 financial results and provided a corporate update....
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2025
ISIN: US7867001049
Sagimet Biosciences Inc
SGMT
LISTED
NASDAQ
Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
News Preview
Phase 1 clinical trial to evaluate the PK of a combination of denifanstat and resmetirom ongoing with data readout expected 1H 2026...
Themefolio
Profiler
Peergroup
© Newsfile
13.11.2025
ISIN: CA41138T1057
Happy Belly Food Group Inc.
HBFG
LISTED
CSE
Happy Belly Food Group's Heal Wellness QSR Announces the Signing of a Franchise Agreement for London, Ontario
News Preview
Toronto, Ontario--(Newsfile Corp. - November 13, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands is pleased to announce that Heal Wellness has signed a franchise agreement for London, Ontario, advancing the brand's disciplined, asset-light expans...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
ISIN: KYG9TY5A1016
Zura Bio Ltd
ZURA
LISTED
NASDAQ
Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates
News Preview
Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2025, and provided recent corporate and pipeline updates.
“Both tibulizumab s...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
ISIN: US8064071025
Henry Schein Inc
HSIC
LISTED
NASDAQ
Henry Schein to Participate in Upcoming Investor Conference in December
News Preview
Henry Schein, Inc., (Nasdaq: HSIC) the world’s largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at the following investor conference in December:
Piper Sandler’s Healthcare Conference at the Lotte New York Palace Hotel, New York, on December 2, 2025, at 9:0...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2025
ISIN: US03828A1016
Applied Therapeutics Inc
APLT
LISTED
NASDAQ
Applied Therapeutics Reports Third Quarter 2025 Financial Results
News Preview
– Update on regulatory strategy for govorestat for the treatment of CMT-SORD following receipt of Type C meeting minutes...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2025
ISIN: CA58490H1073
Medicenna Therapeutics Corp
MDNA
LISTED
TSX
Medicenna Therapeutics Reports Second Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
News Preview
Updated MDNA11 Clinical Data from the ABILITY-1 Study will be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress on 10th December, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2025
ISIN: US45783C2008
Instil Bio Inc
TIL
LISTED
NASDAQ
Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
News Preview
Instil Bio Reports Third Quarter 2025 Financial Results and
Provides Corporate Update...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2025
ISIN: US05153U1079
Aura Biosciences Inc
AURA
LISTED
NASDAQ
Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights
News Preview
Aura Provides Phase 3 CoMpass Trial Completion Guidance: 2026 Enrollment Completion and Q4 2027 Topline Data Readout for the 15-Month Primary Endpoint...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2025
ISIN: US75886F1075
Regeneron Pharmaceuticals Inc
REGN
LISTED
NASDAQ
Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs
News Preview
Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a BCMAxCD3 bispecific antibody as a monotherapy in this setting...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2025
ISIN: US68752L1008
OrthoPediatrics Corp
KIDS
LISTED
NASDAQ
OrthoPediatrics Corp. Expands Specialty Bracing Portfolio with Two New Product Launches
News Preview
WARSAW, Ind., Nov. 13, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the expansion of its OrthoPediatrics Specialty Bracing (“OPSB”) portfolio with two new products launches, the PediHip™ Rigid Brace...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2025
ISIN: US15673T1007
Century Therapeutics Inc
IPSC
LISTED
NASDAQ
Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes
News Preview
PHILADELPHIA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced its first program for Type 1 diabetes (T1D), CNTY-813. The program comprises iPSC-derived beta isle...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
ISIN: AU000000ONE9
Oneview Healthcare Plc
ONE
LISTED
ASX
Appointment of Michael Dowling as Non-Executive Director to the Board of Oneview Healthcare
News Preview
Oneview Healthcare PLC (ASX: ONE) is delighted to announce the appointment of Michael J. Dowling, CEO Emeritus of Northwell Health, as a Non-Executive Director to its Board, effective December 2, 2025.
Michael brings decades of leadership experience in healthcare innovation and transformation at Northwell Health, making it New York's largest hea...
Themefolio
Profiler
Peergroup
© EQS Newswire
13.11.2025
ISIN: TW0006472004
Bora Pharmaceuticals Co Ltd
6472
LISTED
TAI
Bora 3Q25 Delivers Renewed Profitability as Efficiency and Scale Improves
News Preview
EQS Newswire / 13/11/2025 / 11:45 CET/CEST
Strategic realignment powering Bora's dual-engine businesses model HONG KONG SAR - Media OutReach Newswire - 13 November 2025 - Bora Pharmaceuticals (TWSE: 6472) today announced its financial results and operational highlights for third quarter of 2025. Quarterly Business and Financial Highlights ......
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
ISIN: US4577301090
Inspire Medical Systems Inc
INSP
LISTED
NYSE
INSP INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Inspire Medical Systems, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Inspire Medical Systems, Inc. (NYSE: INSP) common stock between August 6, 2024 and August 4, 2025, both dates inclusive (the “Class Period”), have until January 5, 2026 to seek appointment as lead plaintiff of the Inspire Medical class action lawsuit. Captioned City of...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2025
ISIN: US59045L1061
Mersana Therapeutics Inc
MRSN
LISTED
NASDAQ
Day One Biopharmaceuticals to Acquire Mersana Therapeutics
News Preview
Agreement with Day One Biopharmaceuticals provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate of $30.25 per share, for aggregate deal value of up to approximately $285 million...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2025
ISIN: US23954D1090
Day One Biopharmaceuticals Inc
DAWN
LISTED
NASDAQ
Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases
News Preview
Acquisition expands Day One’s portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le)...
Themefolio
Profiler
Peergroup
© EQS Newswire
13.11.2025
ISIN: DE0005227235
Biotest AG
BIO3
LISTED
XETR
Biotest obtains approval for new human fibrinogen Prufibry® in Germany
News Preview
PRESS RELEASE
Biotest obtains approval for new human fibrinogen Prufibry® in Germany
New life-saving therapy for patients with congenital and acquired fibrinogen deficiency
Clinical studies demonstrate efficacy and safety in bleeding control and surgical settings
Important expansion to Biotest’s intensive care and coagulation factor portf......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.11.2025
ISIN: DE0005227235
Biotest AG
BIO3
LISTED
XETR
Biotest erhält Zulassung für neues Human Fibrinogen Prufibry® in Deutschland
News Preview
PRESSEMITTEILUNG
Biotest erhält Zulassung für neues Human Fibrinogen Prufibry® in Deutschland
Neue lebensrettende Therapieoption für Patientinnen und Patienten mit angeborenem und erworbenem Fibrinogenmangel
Klinische Studien belegen Wirksamkeit und Sicherheit in der Blutungskontrolle sowie im chirurgischen Umfeld
Wichtige Erweiterung des ......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
13.11.2025
ISIN: US45408X3089
IGC Pharma, Inc
IGC
LISTED
XASE
USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders
News Preview
POTOMAC, MARYLAND / ACCESS Newswire / November 13, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging Artificial Intelligence ("AI") to develop innovative treatments for Alzheimer's disease, today announced that the United Sta...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
13.11.2025
ISIN: US47010C4096
Jaguar Health, Inc.
JAGX
LISTED
NASDAQ
Jaguar Health Provides Recap of November 8, 2025 Presentation on Groundbreaking Results of Proof-of-Concept Study of Crofelemer for Treatment of Pediatric Intestinal Failure at NASPGHAN Annual Meeting
News Preview
Crofelemer can potentially extend and save lives of microvillus inclusion disease patients, reducing the volume of the total parenteral support (PS) necessary for them to surviveGroundbreaking PS reduction of up to 37% is unprecedented; No approved treatments exist for MVID SAN FRANCISCO, CA / ACCESS Newswire / November 13, 2025 / Jaguar Health, In...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
13.11.2025
ISIN: US83558L2043
Sonoma Pharmaceuticals, Inc.
SNOA
LISTED
NASDAQ
National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced
News Preview
BOULDER, CO / ACCESS Newswire / November 13, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, and animal he...
Themefolio
Profiler
Peergroup
© ActuNews
13.11.2025
ISIN: FR0013286259
Theranexus SA
ALTHX
LISTED
EURONEXT
THERANEXUS : THX Pharma announces the strong success of its approximately EUR 8 million capital increase to support its continued development and strengthen its financial structure
News Preview
Capital increase of €7.8 million through the issuance of 4,356,804 new shares at a unit price of €1.80
The transaction received strong support from existing shareholders, whose demand on irreducible and reducible basis, under the preferential subscription rights amounted to 1,742,660 shares
Lyon, France – November 13,...
Themefolio
Profiler
Peergroup
© ActuNews
13.11.2025
ISIN: FR0013286259
Theranexus SA
ALTHX
LISTED
EURONEXT
THERANEXUS : THX Pharma annonce le vif succès de son augmentation de capital d'environ 8M EUR pour poursuivre son développement et renforcer sa structure financière
News Preview
Augmentation de capital de 7,8M€ par émission de 4 356 804 actions nouvelles au prix unitaire de 1,80 €
L'opération a notamment suscité un fort engagement des actionnaires existants, dont la demande à titre irréductible et réductible, dans le cadre du maintien du DPS, est de 1&nbs...
Themefolio
Profiler
Peergroup
© EQS Newswire
13.11.2025
ISIN: DE0005659700
Eckert & Ziegler SE
EUZ
LISTED
XETR
Eckert & Ziegler Achieves Further Earnings Growth and Double-Digit Sales Growth in the Medical Segment
News Preview
3rd quarter of 2025:
Sales of €75.3 million (previous year: €70.1 million)
EBIT before special items of €15.4 million (previous year: €14.2 million)
Net income of €8.5 million (previous year: €5.3 million)
First 9 months of 2025:
Sales of €224.1 million (previous year: €215.5 million)
EBIT before special items of €50.8 million (previous year: ......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.11.2025
ISIN: DE0005659700
Eckert & Ziegler SE
EUZ
LISTED
XETR
Eckert & Ziegler mit erneutem Ergebniswachstum und zweistelligem Umsatzwachstum im Segment Medical
News Preview
3. Quartal 2025:
Umsatz: 75,3 Mio. € (VJ: 70,1 Mio. €)
EBIT vor Sondereinflüssen: 15,4 Mio. € (VJ: 14,2 Mio. €)
Nettogewinn: 8,5 Mio. € (VJ: 5,3 Mio. €)
9-Monatszeitraum 2025:
Umsatz: 224,1 Mio. € (VJ: 215,5 Mio. €)
EBIT vor Sondereinflüssen: 50,8 Mio. € (VJ: 46,7 Mio. €)
Nettogewinn: 29,9 Mio. € (VJ: 23,4 Mio. €)
Jahresprognose 2025:
Umsatz......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.11.2025
ISIN: DE000A2GS5D8
Dermapharm Holding SE
DMP
LISTED
XETR
Stabiles Ergebnis trotz Portfolioanpassung – Prognose 2025 bestätigt, Markenarzneimittel mit kräftigem Wachstum
News Preview
Stabiles Ergebnis trotz Portfolioanpassung – Prognose 2025 bestätigt, Markenarzneimittel mit kräftigem Wachstum
Kräftiges organisches Umsatzwachstum und robuste Ergebnisentwicklung im margenstarken Markenarzneimittelsegment
Deckungsbeitragsorientierte Bereinigung des Produktportfolios im Parallelimport und der Umbau des Geschäftsmodells der Ar......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.11.2025
ISIN: DE000A2GS5D8
Dermapharm Holding SE
DMP
LISTED
XETR
Stable earnings despite portfolio adjustment - 2025 guidance confirmed, strong growth in branded pharmaceuticals
News Preview
Stable earnings despite portfolio adjustment – 2025 guidance confirmed, strong growth in branded pharmaceuticals
Strong organic revenue growth and robust earnings trend in high-margin "Branded pharmaceuticals" segment
Efforts proceeding as planned to restructure parallel imports product portfolio with focus on contribution margins and to reorg......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
13.11.2025
ISIN: CA58471K2020
Medicus Pharma Ltd.
MDCX
LISTED
TSX
Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
News Preview
THE SKNJCT-003 CLINICAL STUDY EXPANSION INTO THE UNITED KINGDOM TO FURTHER ENABLE GLOBAL PATIENT RECRUITMENT AND CLINICAL DATASET TOWARD A PIVOTAL STUDY PROGRAM PHILADELPHIA, PA / ACCESS Newswire / November 13, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advan...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
ISIN: FR0010331421
Innate Pharma SA
IPH
LISTED
EURONEXT
Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its business update and financial results for the first nine months of 2025.
“This quarter highlights strong execution across our key programs,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “With FDA clearance...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2025
ISIN: BE0003755692
AGFA Gevaert NV
AGFB
LISTED
EURONEXT
The Agfa-Gevaert Group in Q3 2025: continued decline in medical film, strong growth cloud and SaaS in HealthCare IT, soft markets in Digital Print & Chemicals
News Preview
Regulated information November 13, 2025 - 7:45 a.m. CET The Agfa-Gevaert Group in Q3 2025: continued decline in medical film, strong growth cloud and SaaS in HealthCare IT, soft markets in Digital Print & Chemicals...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
ISIN: US4622221004
Ionis Pharmaceuticals Inc
IONS
LISTED
NASDAQ
Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes
News Preview
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today the pricing of $700.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2030 (the “notes”) in a private placement (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Ionis also...
Themefolio
Profiler
Peergroup
© EQS Newswire
13.11.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon veröffentlicht Neunmonatsergebnis und bestätigt Prognose – Pipeline-Fortschritte und starke Partnerschaften prägen Geschäftsjahr 2025
News Preview
Pressemitteilung // 13. November 2025
Formycon veröffentlicht Neunmonatsergebnis und bestätigt Prognose – Pipeline-Fortschritte und starke Partnerschaften prägen Geschäftsjahr 2025
Prognose für 2025 bestätigt – Umsatz- und Ergebnisentwicklung im Rahmen der Erwartungen
FYB202 (Stelara®1-Biosimilar): Markterschließung in den USA und Europa schrei......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.11.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon publishes nine-month results and confirms guidance – Pipeline progress and strong partnerships drive fiscal year 2025
News Preview
Press Release // November 13, 2025
Formycon publishes nine-month results and confirms guidance – Pipeline progress and strong partnerships drive fiscal year 2025
Guidance for 2025 confirmed – Revenue and earnings development in line with expectations
FYB202 (Stelara®1 biosimilar): Market penetration in the US and Europe continues
Significant ......
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2025
ISIN: DK0060257814
Zealand Pharma A/S
ZEAL
LISTED
CPH
Zealand Pharma Announces Financial Results for the First Nine Months of 2025
News Preview
Company announcement – No. 23 / 2025...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
